NKGen Biotech, Inc. Common Stock (NKGN) 10-Year Financial Performance & Capital Metrics

NKGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutGraf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.Show more

Revenue $0
EBITDA -$27M +5.5%
Net Income -$44M +46.6%
EPS (Diluted) -1.54 +71.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -203.31%
Debt/Equity -
Interest Coverage -9.90 +75.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 86.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.55%

ROCE

10Y Avg-659.92%

5Y Avg-659.92%

3Y Avg-929.46%

Latest-326.76%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	426K	77K	0	0
Revenue Growth %	-	-0.82%	-1%	-
Cost of Goods Sold+	30K	18K	1.2M	0
COGS % of Revenue	0.07%	0.23%	-	-
Gross Profit+	396K	59K	-1.2M	0
Gross Margin %	0.93%	0.77%	-	-
Gross Profit Growth %	-	-0.85%	-21.39%	1%
Operating Expenses+	22.26M	24.41M	28.54M	26.97M
OpEx % of Revenue	52.25%	316.95%	-	-
Selling, General & Admin	7.58M	7.66M	14.08M	16.31M
SG&A % of Revenue	17.81%	99.47%	-	-
Research & Development	14.67M	16.75M	14.46M	10.66M
R&D % of Revenue	34.44%	217.48%	-	-
Other Operating Expenses	-84K	-95K	0	0
Operating Income+	-21.86M	-24.35M	-29.75M	-26.97M
Operating Margin %	-51.32%	-316.18%	-	-
Operating Income Growth %	-	-0.11%	-0.22%	0.09%
EBITDA+	-20.62M	-23.14M	-28.54M	-26.97M
EBITDA Margin %	-48.4%	-300.47%	-	-
EBITDA Growth %	-	-0.12%	-0.23%	0.06%
D&A (Non-Cash Add-back)	1.24M	1.21M	1.2M	0
EBIT	-21.95M	-24.44M	-82.2M	-41.51M
Net Interest Income+	-1.31M	-2.31M	-745K	-2.72M
Interest Income	0	0	0	0
Interest Expense	1.31M	2.31M	745K	2.72M
Other Income/Expense	-1.4M	-2.4M	-53.2M	-17.27M
Pretax Income+	-23.26M	-26.75M	-82.95M	-44.23M
Pretax Margin %	-54.6%	-347.36%	-	-
Income Tax+	5K	7K	7K	53K
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-23.27M	-26.75M	-82.95M	-44.29M
Net Margin %	-54.61%	-347.45%	-	-
Net Income Growth %	-	-0.15%	-2.1%	0.47%
Net Income (Continuing)	-23.27M	-26.75M	-82.95M	-44.29M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-1.08	-1.25	-5.38	-1.54
EPS Growth %	-	-0.16%	-3.3%	0.71%
EPS (Basic)	-1.08	-1.25	-5.38	-1.54
Diluted Shares Outstanding	21.45M	21.45M	15.43M	28.83M
Basic Shares Outstanding	21.45M	21.45M	15.43M	28.83M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	612K	350K	1.93M	24K
Cash & Short-Term Investments	351K	117K	26K	0
Cash Only	351K	117K	26K	0
Short-Term Investments	0	0	0	0
Accounts Receivable	67K	96K	26K	24K
Days Sales Outstanding	57.41	455.06	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	22K	4K	313K	0
Total Non-Current Assets+	17.46M	15.98M	14.55M	0
Property, Plant & Equipment	17.37M	15.88M	14.46M	0
Fixed Asset Turnover	0.02x	0.00x	-	-
Goodwill	0	0	0	0
Intangible Assets	89K	97K	92K	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	18.07M	16.33M	16.48M	24K
Asset Turnover	0.02x	0.00x	-	-
Asset Growth %	-	-0.1%	0.01%	-1%
Total Current Liabilities+	55.74M	14.74M	39.45M	0
Accounts Payable	1.71M	975K	11.04M	0
Days Payables Outstanding	20.85K	19.77K	3.35K	-
Short-Term Debt	51.15M	11.65M	9.99M	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	303K	346K	16.77M	0
Current Ratio	0.01x	0.02x	0.05x	-
Quick Ratio	0.01x	0.02x	0.05x	-
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	379K	26K	35.72M	0
Long-Term Debt	0	0	9.93M	0
Capital Lease Obligations	360K	0	0	0
Deferred Tax Liabilities	19K	26K	33K	0
Other Non-Current Liabilities	0	0	25.76M	0
Total Liabilities	56.12M	14.77M	75.17M	0
Total Debt+	51.97M	12.03M	19.92M	0
Net Debt	51.62M	11.92M	19.89M	0
Debt / Equity	-	7.70x	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-16.62x	-10.56x	-39.93x	-9.90x
Total Equity+	-38.05M	1.56M	-58.69M	0
Equity Growth %	-	1.04%	-38.55%	1%
Book Value per Share	-1.77	0.07	-3.80	-
Total Shareholders' Equity	-38.05M	1.56M	-58.69M	0
Common Stock	14K	1K	2K	0
Retained Earnings	-52.42M	-79.18M	-162.13M	0
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.55M	-22.56M	-21.95M	-20.88M
Operating CF Margin %	-45.89%	-292.95%	-	-
Operating CF Growth %	-	-0.15%	0.03%	0.05%
Net Income	-23.27M	-26.75M	-82.95M	-44.29M
Depreciation & Amortization	1.24M	1.65M	1.2M	1.31M
Stock-Based Compensation	93K	69K	4.13M	4.14M
Deferred Taxes	143K	177K	-6.51M	0
Other Non-Cash Items	1.3M	2.27M	59.95M	17.95M
Working Capital Changes	932K	30K	2.23M	0
Change in Receivables	111K	-29K	29K	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	0	2.26M
Cash from Investing+	-459K	-163K	-48K	-13K
Capital Expenditures	-459K	-163K	-48K	0
CapEx % of Revenue	1.08%	2.12%	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	171.62M	-568.64K	0	-13K
Cash from Financing+	20.16M	22.49M	22.16M	20.85M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	161K	-5.72M	20.85M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-20.01M	-22.72M	-22M	-20.88M
FCF Margin %	-46.96%	-295.06%	-	-
FCF Growth %	-	-0.14%	0.03%	0.05%
FCF per Share	-0.93	-1.06	-1.43	-0.72
FCF Conversion (FCF/Net Income)	0.84x	0.84x	0.26x	0.47x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-1711.71%	-	-
Return on Invested Capital (ROIC)	-120.84%	-135.02%	-	-203.31%
Gross Margin	92.96%	76.62%	-	-
Net Margin	-5461.27%	-34745.45%	-	-
Debt / Equity	-	7.70x	-	-
Interest Coverage	-16.62x	-10.56x	-39.93x	-9.90x
FCF Conversion	0.84x	0.84x	0.26x	0.47x
Revenue Growth	-	-81.92%	-100%	-

Frequently Asked Questions

Growth & Financials

NKGen Biotech, Inc. Common Stock (NKGN) reported $0.7M in revenue for fiscal year 2024. This represents a 53% increase from $0.4M in 2021.

NKGen Biotech, Inc. Common Stock (NKGN) grew revenue by 0.0% over the past year. Growth has been modest.

NKGen Biotech, Inc. Common Stock (NKGN) reported a net loss of $44.3M for fiscal year 2024.

Dividend & Returns

NKGen Biotech, Inc. Common Stock (NKGN) had negative free cash flow of $20.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener